These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 11379638)
21. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866 [TBL] [Abstract][Full Text] [Related]
22. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422 [TBL] [Abstract][Full Text] [Related]
23. IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival. Kurtenkov O; Klaamas K; Rittenhouse-Olson K; Vahter L; Sergejev B; Miljukhina L; Shljapnikova L Exp Oncol; 2005 Jun; 27(2):136-40. PubMed ID: 15995632 [TBL] [Abstract][Full Text] [Related]
24. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). Deo SV; Bhutani M; Shukla NK; Raina V; Rath GK; Purkayasth J J Surg Oncol; 2003 Dec; 84(4):192-7. PubMed ID: 14756429 [TBL] [Abstract][Full Text] [Related]
25. [A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer]. Ferrero JM; Namer M; Dufour JF; Largillier R; Creisson A; Teissier E; Machiavello JC; Lallement M; Monticelli J; Abbes M Bull Cancer; 1997 Jan; 84(1):10-6. PubMed ID: 9180853 [TBL] [Abstract][Full Text] [Related]
26. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595 [TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy in stage III breast cancer. Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927 [TBL] [Abstract][Full Text] [Related]
29. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Fisher B; Jeong JH; Anderson S; Wolmark N J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638 [TBL] [Abstract][Full Text] [Related]
30. [Early stage breast cancer: is exclusive radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?]. Daveau C; Savignoni A; Abrous-Anane S; Pierga JY; Reyal F; Gautier C; Kirova YM; Dendale R; Campana F; Fourquet A; Bollet MA Cancer Radiother; 2011 Apr; 15(2):106-14. PubMed ID: 21084207 [TBL] [Abstract][Full Text] [Related]
31. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles]. Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752 [TBL] [Abstract][Full Text] [Related]
32. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer]. Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634 [TBL] [Abstract][Full Text] [Related]
33. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583 [TBL] [Abstract][Full Text] [Related]
34. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257 [TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K; Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922 [TBL] [Abstract][Full Text] [Related]
36. Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy? Daveau C; Savignoni A; Abrous-Anane S; Pierga JY; Reyal F; Gautier C; Kirova YM; Dendale R; Campana F; Fourquet A; Bollet MA Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1452-9. PubMed ID: 20605368 [TBL] [Abstract][Full Text] [Related]
37. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040 [TBL] [Abstract][Full Text] [Related]
38. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial. Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512 [TBL] [Abstract][Full Text] [Related]
39. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316 [TBL] [Abstract][Full Text] [Related]
40. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer. Erselcan T; Kairemo KJ; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H Br J Cancer; 2000 Feb; 82(4):777-81. PubMed ID: 10732745 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]